Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18953127 | 1.00 | KMT2A (0.43) | KMT2ANOD2RENCTSKCTSS | |
| SCHEMBL9224622 | 1.00 | KMT2A (0.43) | KMT2ANOD2RENCTSKCTSS | |
| SCHEMBL9696051 | 0.89 | FOLH1 (0.48) | KMT2ACTSKCTSSCTSLCTSB | |
| SCHEMBL10976677 | 0.89 | FOLH1 (0.48) | KMT2ACTSKCTSSCTSLCTSB | |
| SCHEMBL10606976 | 0.89 | CTSK (0.47) | RENCTSKCTSSCTSLCTSB | |
| SCHEMBL8461423 | 0.89 | CTSK (0.47) | RENCTSKCTSSCTSLCTSB | |
| SCHEMBL7509222 | 0.89 | CTSK (0.47) | RENCTSKCTSSCTSLCTSB | |
| SCHEMBL11120073 | 0.87 | NOD1 (0.46) | KMT2ARENCTSKCTSSCTSL | |
| SCHEMBL11165901 | 0.87 | CTSS (0.53) | RENCTSKCTSSCA1CA2 | |
| SCHEMBL10788830 | 0.84 | REN (0.47) | KMT2ARENCTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389643-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2023-05-03 | — | — | EP | disclosed |
| CN-108884132-B | Muramyl peptide derivatives a compound their synthesis and their use | 巴拉特生物技术国际有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3387005-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2022-08-24 | — | — | EP | disclosed |
| US-20220056080-A1 | Muramyl Peptide Derivatives | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2022-02-24 | — | — | US | disclosed |
| US-10927147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2021-02-23 | — | — | US | disclosed |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2020-03-03 | — | — | US | disclosed |
| US-20180371023-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2018-12-27 | — | — | US | disclosed |
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| EP-3389643-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | Bharat Biotech International Limited (IN) | 2018-10-24 | — | — | EP | disclosed |
| EP-3387005-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | Bharat Biotech International Limited (IN) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017103944-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017098529-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056080-A1 | Muramyl Peptide Derivatives | NOD2, NGLY1, LNPEP | KMT2A 3063/4885NOD2 1/4885REN 3471/4885 |
| US-20180360957-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | NOD2, HM13, HLA-DRB1 | KMT2A 2963/4885NOD2 1/4885REN 3492/4885 |
| US-10576147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | NOD2, HM13, QRFPR | KMT2A 2936/4885NOD2 1/4885REN 3267/4885 |
| US-20180371023-A1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | NOD2, MICA, TLR9 | KMT2A 2775/4885NOD2 1/4885REN 3414/4885 |
| US-10927147-B2 | Muramyl peptide derivative compound, synthesis and uses thereof | NOD2, TLR9, MICA | KMT2A 2643/4885NOD2 1/4885REN 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.